We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

41 hedge funds and large institutions have $20M invested in vTv Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

0.32% more ownership

Funds ownership: 0.95% → 1.27% (+0.32%)

7% less funds holding

Funds holding: 44 → 41 (-3)

9% less capital invested

Capital invested by funds: $22.1M → $20M (-$2.05M)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
41
Holders Change
-3
Holders Change %
-6.82%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GC
GMT Capital
Georgia
+$5.75M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.81M
3
RA
Royce & Associates
New York
+$845K
4
JP Morgan Chase
JP Morgan Chase
New York
+$719K
5
CWG
C WorldWide Group
Denmark
+$599K

Top Sellers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
-$1.04M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$827K
3
CS
Candriam SCA
Luxembourg
-$541K
4
SM
Sabby Management
Florida
-$267K
5
Renaissance Technologies
Renaissance Technologies
New York
-$215K
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
1
GMT Capital
Georgia
$3.82M +$5.75M +23,478 New
Franklin Resources
2
Franklin Resources
California
$3.4M -$90.6K -370 -2%
Massachusetts Financial Services
3
Massachusetts Financial Services
Massachusetts
$1.85M +$28.6K +117 +1%
RA
4
Royce & Associates
New York
$1.48M +$845K +3,450 +61%
BlackRock
5
BlackRock
New York
$1.39M -$14.2K -58 -0.7%
JP Morgan Chase
6
JP Morgan Chase
New York
$1.33M +$719K +2,938 +56%
Fidelity Investments
7
Fidelity Investments
Massachusetts
$1.2M +$1.81M +7,396 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.19M +$413K +1,687 +30%
SFM
9
Sphera Funds Management
Israel
$1.15M – – –
State Street
10
State Street
Massachusetts
$424K -$45.8K -187 -7%
CWG
11
C WorldWide Group
Denmark
$399K +$599K +2,449 New
Northern Trust
12
Northern Trust
Illinois
$391K +$117K +479 +25%
Millennium Management
13
Millennium Management
New York
$387K +$198K +809 +52%
BCM
14
Bridgeway Capital Management
Texas
$305K – – –
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$220K -$827K -3,380 -71%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$177K +$10.5K +43 +4%
Morgan Stanley
17
Morgan Stanley
New York
$133K +$1.47K +6 +0.7%
Deutsche Bank
18
Deutsche Bank
Germany
$121K +$82.2K +336 +81%
JGC
19
J. Goldman & Co
New York
$106K +$159K +650 New
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$98K +$148K +605 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$90K – – –
Renaissance Technologies
22
Renaissance Technologies
New York
$81K -$215K -880 -64%
TCIM
23
TIAA CREF Investment Management
New York
$61K – – –
Charles Schwab
24
Charles Schwab
California
$50K – – –
California State Teachers Retirement System (CalSTRS)
25
California State Teachers Retirement System (CalSTRS)
California
$46K – – –
1
2

VTVT Hedge Fund Activity: Q1 2018 in Review

41 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2018, worth a combined $20M — down 9.3% from $22.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of VTVT and 5 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 13 added.

The largest buyer was GMT Capital, opening a new position worth an estimated $5.75M. The largest seller was Ameriprise, exiting entirely with an estimated $1.04M sold.

  • 41 institutional investors held vTv Therapeutics (VTVT) as of Q1 2018, down from 44 in Q4 2017.
  • Funds reported $20M of vTv Therapeutics stock for Q1 2018, down 9.3% quarter-over-quarter.
  • 5 funds opened new vTv Therapeutics positions in Q1 2018 and 8 closed out, a net change of -3 holders.
  • The largest vTv Therapeutics buyer in Q1 2018 was GMT Capital, an estimated $5.75M added.
  • The largest vTv Therapeutics seller in Q1 2018 was Ameriprise, an estimated $1.04M sold.

Based on aggregated 13F filings for Q1 2018.